Wells Fargo
CSBR icon

Wells Fargo’s Champions Oncology CSBR Stock Holding History

Wells Fargo’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47
Closed -$230 – 7012
2024
Q1 		$230 Buy
47
+1
+2% +$6 ﹤0.01% 6461
2023
Q4 		$259 Buy
46
+3
+7% +$17 ﹤0.01% 6538
2023
Q3 		$267 Sell
43
-2
-4% -$13 ﹤0.01% 6514
2023
Q2 		$287 Buy
45
+2
+5% +$10 ﹤0.01% 6597
2023
Q1 		$173 Buy
43
+1
+2% +$4 ﹤0.01% 6811
2022
Q4 		$189 Buy
42
+1
+2% +$7 ﹤0.01% 6632
2022
Q3 		$0 Sell
41
-3
-7% -$25 ﹤0.01% 6748
2022
Q2 		$0 Buy
44
+3
+7% +$23 ﹤0.01% 6892
2022
Q1 		$0 Buy
41
+1
+3% +$8 ﹤0.01% 7151
2021
Q4 		$0 Hold
40
– – ﹤0.01% 7291
2021
Q3 		$0 Buy
40
+4
+11% +$41 ﹤0.01% 7013
2021
Q2 		$0 Sell
36
-53,746
-100% -$545K ﹤0.01% 6958
2021
Q1 		$608K Buy
53,782
+43,450
+421% +$504K ﹤0.01% 4584
2020
Q4 		$112K Sell
10,332
-4,069
-28% -$42K ﹤0.01% 5317
2020
Q3 		$133K Buy
14,401
+10,704
+290% +$95.3K ﹤0.01% 5148
2020
Q2 		$35K Buy
3,697
+3,660
+9,892% +$31.2K ﹤0.01% 5573
2020
Q1 		$0 Sell
37
-24,963
-100% -$175K ﹤0.01% 6267
2019
Q4 		$208K Sell
25,000
-140,950
-85% -$870K ﹤0.01% 4929
2019
Q3 		$938K Buy
165,950
+16,850
+11% +$109K ﹤0.01% 3888
2019
Q2 		$1.17M Buy
149,100
+78,250
+110% +$686K ﹤0.01% 3759
2019
Q1 		$694K Buy
70,850
+68,850
+3,443% +$686K ﹤0.01% 4144
2018
Q4 		$16K Sell
2,000
-3,500
-64% -$40.2K ﹤0.01% 5821
2018
Q3 		$96K Sell
5,500
-1,000
-15% -$8.9K ﹤0.01% 5376
2018
Q2 		$41K Buy
6,500
+500
+8% +$2.4K ﹤0.01% 5646
2018
Q1 		$22K Buy
6,000
+1,303
+28% +$4.86K ﹤0.01% 5783
2017
Q4 		$18K Buy
+4,697
New +$16.7K ﹤0.01% 5811

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo's CSBR Position: Q2 2024 in Review

Wells Fargo sold out of Champions Oncology (CSBR) in Q2 2024, closing a stake of 47 shares — an estimated $230 sold.

Wells Fargo first reported a position in CSBR in Q4 2017 and held it in 26 quarters. The position peaked at $1.17M in Q2 2019. 23 funds tracked by Wall St. Rank hold CSBR as of Q2 2024.

  • Wells Fargo reported no remaining Champions Oncology position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 47 Champions Oncology shares in Q2 2024, an estimated $230.
  • Wells Fargo first reported a position in Champions Oncology in Q4 2017 and held it in 26 quarters.
  • Wells Fargo's Champions Oncology position peaked at $1.17M in Q2 2019.
  • 23 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.